Gene Bio Medical announces partnership with HI³ as part of PREPARED project

TORONTO — Gene Biotechnology Enterprises Ltd., also known as Gene Bio Medical, announces its strategic partnership with the Canadian Hub for Health Intelligence & Innovation in Infectious Diseases (HI³). This collaboration forms part of an initiative titled “Pandemic preparedness engaging primary care and emergency departments (PREPARED).”

The project is led by Dr. Andrew Pinto, Founder and Director of the Upstream Lab and Associate Professor at the University of Toronto. Gene Bio Medical has been invited by Dr. Pinto to partner on the commercialization and manufacturing aspects of the project, which aims to engage primary care and emergency departments across six provinces in Canada. With its four-pronged objective – integrating point-of-care tests, improving surveillance, linking patients to trials, and accelerating the creation of diagnostics – the project marks a significant step towards improving pandemic preparedness.

HI3, one of the five hubs evaluating R&D projects for the Canada Biomedical Research Fund (CBRF) and Biosciences Research Infrastructure Fund (BRIF), is a coalition of academic, hospital, research networks, industry, government, not-for-profit, and community partners, including the University of Toronto. Its mission is to collaboratively bolster Canada’s biomanufacturing capacity to ensure a fast and coordinated response to future pandemics and infectious health threats.

This partnership marks the third of its kind for Gene Bio Medical within the CBRF/BRIF program. Gene Bio Medical says that they continue to be sought out by leading R&D organizations.

Jessica Hu, CEO of Gene Bio Medical, commented, “We’re proud to collaborate with HI³ and contribute to the PREPARED project. Our continued involvement in initiatives under the CBRF/BRIF program demonstrates our commitment to advancing global health solutions.”